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Abstract
Background: Despite being associated with worse prognosis in patients with COVID-19, systematic 
determination of myocardial injury is not recommended. The aim of the study was to study the effect of 
myocardial injury assessment on risk stratification of COVID-19 patients.
Methods: Seven hundred seven consecutive adult patients admitted to a large tertiary hospital with 
confirmed COVID-19 were included. Demographic data, comorbidities, laboratory results and clinical 
outcomes were recorded. Charlson comorbidity index (CCI) was calculated in order to quantify the 
degree of comorbidities. Independent association of cardiac troponin I (cTnI) increase with outcomes 
was evaluated by multivariate regression analyses and area under curve. In addition, propensity-score 
matching was performed to assemble a cohort of patients with similar baseline characteristics.
Results: In the matched cohort (mean age 66.76 ± 15.7 years, 37.3% females), cTnI increase above 
the upper limit was present in 20.9% of the population and was associated with worse clinical outcomes, 
including all-cause mortality within 30 days (45.1% vs. 23.2%; p = 0.005). The addition of cTnI to  
a multivariate prediction model showed a significant improvement in the area under the time-dependent 
receiver operating characteristic curve (0.775 vs. 0.756, DC-statistic = 0.019; 95% confidence interval 
0.001–0.037). Use of renin–angiotensin–aldosterone system inhibitors was not associated with mortal-
ity after adjusting by baseline risk factors.
Conclusions: Myocardial injury is independently associated with adverse outcomes irrespective of 
baseline comorbidities and its addition to multivariate regression models significantly improves their 
performance in predicting mortality. The determination of myocardial injury biomarkers on hospital 
admission and its combination with CCI can classify patients in three risk groups (high, intermediate 
and low) with a clearly distinct 30-day mortality. (Cardiol J 2020; 27, 4: xx–xx)
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Introduction
As of June 19, 2020, coronavirus disease 2019 
(COVID-19) has affected more than 8 million people, 
causing more than 440,000 deaths worldwide [1]. 
To lessen the burden on health care systems and 
provide better care, prediction models that provide 
efficient diagnosis and prognosis of the disease are 
needed. Identifying people at high risk of experienc-
ing worse outcomes might help the clinician in the 
routine decision-making process [2–4].
COVID-19 infection may have major repercus-
sions for the cardiovascular system [5, 6]. Recent 
investigations suggest a high prevalence of myo-
cardial injury in these patients that can be detected 
by an elevation of some cardiac biomarkers, such 
as cardiac troponins [2, 7, 8]. 
Myocardial injury defined as troponin eleva-
tion has been consistently associated with mortal-
ity in a variety of situations, including sepsis and 
pneumonia. The value of measuring troponins to 
better stratify patients and guide management has 
been suggested for COVID-19, but solid evidence 
is pending to support its incremental value and 
systematic evaluation. Many previous studies 
have been reported to be at high risk of bias [3]. 
Cardiovascular morbidity has also been associated 
with both worse outcomes in COVID-19. Whether 
the excess of mortality in patients with myocardial 
injury can be explained by the higher prevalence 
of comorbidities in this population is still a subject 
of discussion [4, 9–14]. 
The purpose of this study is to describe the 
association between troponin elevation and mortal-
ity and whether this link is irrespective of patient 
comorbidities, as well as to evaluate its incremental 
benefit as a risk stratification tool. 
Methods
Study population
Between March 18, and March 23, 2020, con-
secutive patients aged 18 years and older admitted 
to a large tertiary hospital with COVID-19 infection 
were retrospectively included with prospective 
follow-up. Diagnosis of COVID-19 infection was 
established by positive test for severe acute res-
piratory syndrome coronavirus 2 (SARS-CoV-2) 
viral RNA in nasopharyngeal swab by real-time 
reverse-transcription polymerase chain reaction 
according to World Health Organization interim 
guidance [15]. The only exclusion criterion was 
primary cardiac presentation, i.e. type 1 myocardial 
infarction. This study was approved by the Local 
Ethics Committee and written informed consent 
was waived.
Patients were treated with lopinavir/ritonavir 
and hydroxychloroquine unless contraindicated. 
Antibiotics, glucocorticoid and other immunosup-
pressive agents (i.e. tocilizumab) were also used 
at physician discretion according to the in-hospital 
consensus protocol.
Data collection
Baseline data, including demographics, medi-
cal history and laboratory tests were collected from 
the local Electronic Medical Records. Previous 
concomitant conditions were carefully evaluated 
and age-adjusted Charlson comorbidity index (CCI; 
Suppl. Table S1) [16] was calculated in order to 
quantify the patient’s degree of comorbidity. All 
patients were followed for 1 month. Time from 
symptoms to admission, length of hospital stays, 
illness severity, use of non-invasive ventilation, 
mechanical ventilation and all-cause mortality 
were recorded. 
Development of acute respiratory distress 
syndrome (ARDS) according to the Berlin defini-
tion, with arterial partial pressure of oxygen (PaO2) 
and fraction of inspired oxygen (FiO2) ratio < 300 
mmHg was used to identify severe manifesta-
tions of the disease. When PaO2 was not available, 
peripheral capillary oxygen saturation (SpO2) was 
used to estimate PaO2 [17]. Acute kidney injury 
was identified according to the Kidney Disease: 
Improving Global Outcomes definition [18].
Laboratory procedures
An in-hospital protocol developed by the infec-
tious diseases department was made available since 
the beginning of the local outbreak. Routine blood 
examination on admission with serum biochemi-
cal tests, cardiac troponin, complete blood count, 
coagulation profile and D-Dimer was part of this 
protocol. Abbott high-sensitivity cardiac troponin I 
(cTnI) was used for analysis of cTnI. Cut-off normal 
value was ≤ 14 ng/L. 
During hospitalization, the timing, content and 
repetition of successive tests were indicated by the 
treating physicians. Peak values during hospitali-
zation of creatinine, cTnI, hematocrit, D-Dimer, 
B-type natriuretic peptide and C-reactive protein 
(CRP) were recorded.
Ethical approval
Approval from the local ethics committee 
(Comite etico de Investigacion clinica GAE Ramon 
y Cajal Area 4) was granted as per local protocol.
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Statistical analysis
Patients were divided in two groups: with and 
without myocardial injury on admission, defined 
as cTnI levels greater than the 99th percentile of 
a healthy population [19]. 
Multivariate Cox proportional hazards re-
gression models were used to determine the as-
sociation of cTnI with all-cause mortality within 
30 days in hospitalized patients with COVID-19 
disease (see Supplementary material: statistical 
analysis). Results were expressed as hazard ratios 
with 95% confidence intervals (CIs). Variables 
were selected a priori based on previous clinically 
related studies, clinical knowledge and practicality 
of measurement in acute medical emergencies. 
Variables were excluded if they had high multicol-
linearity. The number of predictors was restricted 
based on the total number of outcomes. 
Kaplan-Meier survival curves were presented 
to compare survival in the groups of patients with-
out myocardial injury versus those with myocardial 
injury. For analysing the interaction of comorbidi-
ties and cTnI, four groups were defined: no myo-
cardial injury and CCI ≤ 4 (n = 411); no myocardial 
injury and CCI > 4 (n = 148); myocardial injury 
and CCI ≤ 4 (n = 46) and myocardial injury and 
CCI > 4 (n = 102). Time-dependent receiver-operator 
characteristic (ROC) curves were used to evaluate the 
incremental benefit of cTnI for predicting all-cause 
mortality. Areas under the ROC curves were calculated 
and compared. The integrated discrimination improve-
ment index (IDI) and the continuous net reclassifica-
tion improvement (cNRI) were also calculated.
Given the differences in the baseline character-
istics between patients in the two groups (Table 1), 
a propensity score matching was performed using 
a multivariable logistic regression model with the 
use of myocardial injury as the dependent variable 
and all the baseline characteristics outlined in Ta-
ble 1 as covariates. 1:1 matching was performed 
without replacement and with a calliper width equal 
to 0.2. Standardized differences were estimated 
before and after matching to assess balance. In 
the matched cohort, differences between groups 
were analysed with chi-squared test or sign test 
of matched pairs as appropriate.
Data were analysed using Stata 14.2 software 
(StataCorp LLC, Texas, United States) and R sta-
tistics version 3.6.3 (R Foundation for Statistical 
Computing, Vienna, Austria). For all the statistical 
analysis, a two-tailed p value of less than 0.05 was 
considered significant.
Table 1. Baseline characteristics before and after propensity-score matching.
Characteristics Before matching After matching
Myocardial  
injury  
(n = 148)
No  
myocardial 
injury  
(n = 559)
Standardized 
differences, 
%
Myocardial 
injury  
(n = 112)
No  
myocardial 
injury  
(n = 112)
Standardized 
differences, 
%
Age [years] 78.7 63.4 114.0 76.3 75.5 6.1
Sex 48.0% 34.5% 27.5% 42.9% 43.8% 1.8%
Hypertension 76.4% 43.6% 70.1% 72.3% 77.7% 11.6%
Use of RAAS inhibitors 54.7% 25.8% 61.7% 50.0% 50.0% 0.0%
Diabetes (%) 24.3% 19.1% 12.6% 26.8% 23.2% 8.7%
Dyslipidemia 45.3% 31.1% 29.4% 44.6% 38.3% 13.0%
CKD 30.4% 6.08% 66.2% 17.9% 21.4% 9.7%
AF 25.0% 9.1% 43.1% 17.9% 22.3% 12.1%
IHD 15.5% 9.3% 19.0% 15.2% 11.6% 10.9%
HF history 32.4% 8.6% 61.6% 20.5% 22.3% 4.6%
Cerebrovascular disease 12.8% 4.1% 31.6% 8.0% 8.0% 0.0%
PAD 7.4% 2.1% 24.9% 3.6% 5.4% 8.4%
Cancer history 16.2% 9.8% 19.0% 17.0% 17.0% 0.0%
COPD 16.9% 7.5% 28.9% 14.3% 15.2% 2.7%
CCI (points) 6.5 3.2 115.1 5.4 5.4 0.6
AF — atrial fibrillation; CCI — Charlson comorbidity index; CKD — chronic kidney disease; COPD — chronic obstructive pulmonary disease; 
HF — heart failure; IHD — ischemic heart disease; PAD — peripheral artery disease; RAAS — renin–angiotensin–aldosterone system
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Results
Baseline characteristics
A total of 707 consecutive patients with con-
firmed COVID-19 were enrolled into the study (Fig. 1). 
Mean age was 66.6 ± 15.7 years and 37.3% were 
women. Prevalence of cardiovascular risk factors 
was high. The most common risk factor was hyper-
tension (50.5%) followed by dyslipidemia (34.1%) 
and diabetes mellitus (20.2%). Chronic kidney 
disease was present in 11.2% of patients. Cancer 
history was also a relatively frequent condition, 
being present in almost 11.2% of patients. Median 
CCI was 3 (IQR 1 to 6). 
There were significant differences in baseline 
characteristics between the two groups (Table 1). 
Patients with myocardial injury were older (78.7 
vs. 63.4, p < 0.001) and were more frequently 
male (48.0% vs. 34.5%, p = 0.003). The burden of 
comorbidities was also higher in this group (median 
CCI of 6 vs. 3, p < 0.001). 
A propensity-score matching was performed 
and 112 patients with myocardial injury on admission 
were matched with 112 patients without myocardial 
injury. After matching, an adequate comparability 
was shown by a decrease of the standardized differ-
ences to less than 20% for all covariates (Table 1).
Laboratory findings
Elevated cardiac troponin was patent in 20.9% 
of patients. The median level of cTnI on admission 
was 28.2 ± 15.7 ng/L) and mean peak level during 
hospitalization was 83.8 ± 68.7 ng/L. During hos-
pitalization troponin levels increased in 57 (8.1%) 
of patients.
D-Dimer levels were elevated on admission 
in 70.6% of cases. Correlation between D-Dimer 
and peak troponin levels was weak (Spearman’s r 
0.24, p < 0.001).
Clinical outcomes
Of the 707 hospitalized patients, 368 (52.1%) 
had severe manifestation of COVID-19 defined by 
ARDS criteria, and 7.6% were admitted to the in-
tensive care unit (ICU). Acute kidney injury (AKI) 
on admission was present in 9.6% of patients and 
12.7% of cases developed AKI during hospitaliza-
tion. Non-invasive mechanical ventilation was used 
in 6.5% of patients. After 1-month follow-up, 501 
(70.9%) patients were discharged, 140 (19.8%) 
patients died and 66 (9.3%) patients remained 
hospitalized.
Median time-to-discharge was 9 days (IQR 
5 to 14). The median time from initiation of symp-
toms to admission was 6 days (IQR 3 to 8), while 
the median time from onset of illness to death was 
days 14 days (IQR 9 to 19).
In the matched cohort all-cause mortality 
within 30 days was higher in those with cTnI eleva-
tion (41.1% vs. 23.2%; p = 0.005; Table 2). They 
also required more often non-invasive ventilation 
(15.2% vs. 5.4%, p = 0.016). However, there were 
no differences regarding ICU admission (6.3% vs. 
4.5%, p = 0.527).
In the multivariate-adjusted Cox proportional 
hazard regression model, cTnI elevation was inde-
pendently associated with a higher risk of all-cause 
mortality within 30 days. Age, CRP and creatinine on 
admission were also independent prognostic factors 
(Table 3). In a second Cox model, adjusted for CCI 
to account for age and comorbidity, cTnI elevation 
was also independently associated with higher risk 
of mortality (hazard ratio 2.31, 95% CI 1.57–3.39, 
p < 0.001).
Figure 2 shows Kaplan-Meier survival curves 
by myocardial injury groups (Fig. 2A) and by myo-
cardial injury and CCI (Fig. 2B). 
The addition of myocardial injury to the final 
multivariate clinical Cox model showed a signifi-
cant improvement in the area under the ROC curve 
(0.77 vs. 0.79; Fig. 3). The C-statistic for the base-
line clinical model was 0.756, while the addition of 
cTnI increased it to 0.775 (DC-statistic = 0.019; 
95% CI 0.001–0.037). The cNRI was 35.2% (95% 
CI 0.4–45.5%, p = 0.047) while the IDI showed an 
incremental predictive ability (p< 0.001; Table 4).
Figure 1. Patient selection. Flowchart showing the 
successive steps taken during the study; COVID-19 — 
coronavirus disease 2019; ACS — acute coronary syn-
drome; APE — acute pulmonary edema.
711 patients
admitted for COVID-19
were screened
3 patients excluded:
2 ACS and 1 APE
1 lost to follow-up
707 patients included 
in the study
708 patients
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Table 2. Outcomes and complications in the matched cohort.
With myocardial injury  
(n = 112)
Without myocardial injury  
(n = 112)
P
ARDS 83 (74.1%) 65 (58.0%) 0.013
Non-invasive ventilation 17 (15.2%) 6 (5.4%) 0.016
ICU admission 7 (6.3%) 5 (4.5%) 0.527
Hospital stay, median days (IQR) 11 (6 to 17) 9 (5 to 13) 0.934
Mortality 46 (41.1%) 26 (23.2%) 0.005
ARDS — acute respiratory distress syndrome; ICU — intensive care unit; IQR — interquartile range
Figure 2. Event-free survival over time with the Kaplan-Meier method for myocardial injury (M. injury; A) and myo-
cardial injury and Charlson comorbidity index (CCI; B). 
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Table 3. Multivariate Cox regression analysis. 
Predictors on admission Univariable analysis;  
HR (95% CI)
P Multivariable analysis; 
HR (95% CI)
P
Sex 1.108 (0.787–1.562) 0.556
Age (per year) 1.080 (1.063–1.097) < 0.001 1.069 (1.051–1.087) < 0.001
Myocardial injury 4.355 (3.112–6.093) < 0.001 1.716 (1.182–2.492) 0.005
Hypertension 1.960 (1.380–2.784) < 0.001
RAAS inhibitors use 1.700 (1.210–2.388) 0.002
Hematocrit (per % decrease) 0.929 (0.905–0.954) < 0.001
Creatinine (per mg/dL) 1.469 (1.304–1.655) < 0.001 1.291 (1.103–1.511) < 0.001
D-Dimer (per ng/mL) 1.011 (0.986–1.036) 0.390
C-reactive protein (per mg/L) 1.002 (1.002–1.003) < 0.001 1.002 (1.001–1.003) < 0.001
CCI (per point increase) 1.274 (1.216–1.335) < 0.001
CCI — Charlson comorbidity index; CI — confidence interval; HR — hazard ratio; RAAS — renin–angiotensin–aldosterone system
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Use of RAAS inhibitors
Although use of renin–angiotensin–aldoster-
one system (RAAS) inhibitors was more prevalent 
in patients who died (42.9% vs. 29.1%, p < 0.001), 
no independent association for use of RAAS with 
mortality was found after adjusting for hyperten-
sion and other risk factors.
Discussion
According to available research, this is 
the largest cohort of hospitalized patients with 
COVID-19 outside the Hubei province that proves 
the incremental value of myocardial injury on ad-
mission for predicting all-cause 30 day mortality. 
This has been proved by a model which includes 
classical predictors, a second model including an 
index accounting for comorbidities, age and a pro-
pensity score analysis. According to the present 
data, combining the CCI (which is readily available 
for clinicians) with the presence of myocardial 
injury can classify patients into three risk groups 
(high, intermediate and low) with clearly distinct 
30-day mortality (Fig. 2B).  
In contrast to previous studies, time-depend-
ent ROC curves were estimated to evaluate if the 
determination of cTnI provides additional infor-
mation over other accessible clinical information. 
Proving this incremental value is crucial if a sys-
tematic determination of cTnI is being considered.
In the current study up to 1 in every 5 
COVID-19 patients presented with myocardial injury. 
This finding is consistent with previous observations 
[2, 8–10]. The mechanism of troponin elevation is not 
yet clearly understood and evidence in this matter has 
yet to emerge. Whether it is a systemic consequence 
of a patient’s hemodynamic status and hypoxia or 
direct myocardial damage is subject to debate. In-
flammatory infiltration of the myocardial tissue by 
the virus has been proposed by some investigators 
[20, 21]. Another hypothesis is that the cytokine 
storm syndrome may provoke subclinical diastolic 
left ventricular impairment by itself [22].
Comorbidities are prevalent in patients 
hospitalized because of COVID-19, establishing 
a possible confounding factor with regards to cTnI 
elevation [2, 23]. However, the present results 
prove otherwise. The CCI is a validated clinical 
score that has demonstrated its usefulness both in 
a chronic and acute setting. It is related to the mor-
tality of sepsis, pneumonia and seasonal influenza 
[13, 24–27]. In the cardiovascular acute setting, it 
has also been used as a reliable prognostic tool in 
situations such as acute myocardial infarction [28].
In the present cohort the presence of myo-
cardial injury was significantly associated with an 
increased mortality risk, an observation that was 
consistent among all patient subgroups. Even in 
patients with low prevalence of comorbidities, 
such as patients with a CCI below 4, cTnI main-
tained its prognostic value. Use of cTnI among 
low-risk individuals reclassified 6.5% of patients, 
assimilating their predicted 30-day mortality risk 
to that of higher-risk individuals (from 10.1% to 
Table 4. Evaluation of the incremental value of myocardial injury to the multivariate model. 
Estimate (95% CI) P
C-statistic multivariate Cox model with myocardial injury and CCI 0.775 (0.739–0.811) –
C-statistic multivariate Cox model without myocardial injury 0.756 (0.720–0.792) –
DC-statistic 0.019 (0.001–0.037) 0.025
Continuous net, % 35.2 (0.4–42.5) 0.047
Integrated discrimination improvement index 0.034 (0.009–0.073) < 0.001
CCI — Charlson comorbidity index; CI — confidence interval
False–positive ratio
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Figure 3. Receiver operating characteristic curves for 
the baseline Cox model (including Charlson comorbidity 
index [CCI]) in blue and for the multivariate model with 
the addition of myocardial injury in red; AUC — area 
under the curve; M. injury — myocardial injury.
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28.3%). Similarly, the use of cTnI among patients 
with a CCI ≥ 4 reclassified 40.1% of them as very 
high risk (with a predicted mortality that shifted 
from 36.1% to 47.0%). Among those patients who 
died, 48.6% had presented with myocardial injury. 
Therefore, troponin elevation may be interpreted 
as an early warning sign with impending clinical 
implications, identifying those patients who might 
require careful patient monitoring.
Area under the ROC curve (AUC) is a popu-
lar measure of the incremental discrimination 
provided by a risk factor in a prediction model. 
However, the change in the area under the curve 
(DAUC) strongly depends on the baseline model. 
As demonstrated by Pencina et al. [29], a new 
predictor with a strong effect added to a good 
baseline model may result in a miniscule DAUC. 
Two other indexes have been proposed to measure 
the improvement in discrimination: the IDI and the 
cNRI, which are less dependent on the strength of 
the baseline model. Including cTnI in the model 
raised the AUC by 0.02 and the cNRI was 35.2%.
Given this incremental value, cost consid-
erations should be studied before systematically 
recommending the determination of cTnI in pa-
tients with suspected COVID-19. Until then and 
according to the present data, cTnI could be used 
to aid physicians in classifying patients in the 
emergency department, especially those who are 
severely ill and might require closer vigilance and 
more intensive therapies.
The present study was executed on earlier phases 
of the pandemic, and most patients were treated with 
hydroxychloroquine. This agent has been recently 
been identified as being ineffective and even potentially 
harmful in COVID-19 patients [30]. Notwithstanding 
it was not thought to have any plausible interactions 
on the results of the current investigation.
Recently, it has been criticized that prediction 
models published during the current COVID-19 
outbreak are poorly reported and sometimes lack 
statistical rigor [3]. Herein, an effort was made to 
adhere to the TRIPOD (transparent reporting of 
a multivariable prediction model for individual 
prognosis or diagnosis) reporting guidelines in 
order to minimize the risk of bias.
Limitations of the study
First, this is an observational single-center 
study and interventions were indicated by the 
treating physicians; however, adherence to the 
local consensus protocol resulted in uniform treat-
ment choices and has made cTnI values available in 
the quasi-totality of patients. Secondly, the effect 
on downstream testing has not been evaluated, 
which may limit the universalization of the findings. 
Also, restrictions inherent to the emergence of an 
infectious outbreak limit the availability of some 
data. Last, because of the necessity of prompt and 
robust scientific data during the current outbreak, 
some observations were censored at the end of the 
observational period; given that less than 10% of 
patients remained hospitalized at the end of follow-
up, no relevant variations of the outcome analysis 
might be expected.
Conclusions
Myocardial injury is strongly associated with 
all-cause mortality within 30 days in hospitalized 
patients with confirmed COVID-19, even after 
adjusting for comorbidities and other possible 
cofounders. Its inclusion in multivariate prediction 
models significantly enhanced their performance. 
Determination of cardiac troponin I on admission 
improves risk-stratification and its elevation is 
a caveat that should raise awareness of the pos-
sibility of adverse outcomes.
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